July 21, 2021
Aurobindo Receives FDA Approval for Nifedipine Extended-Release Tablets USP, 30mg, 60mg, and 90mg
East Windsor, N.J. –Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Nifedipine Extended-Release Tablets USP, 30 mg, 60mg and 90 mg. Aurobindo Pharma’s Nifedipine Extended-Release Tablets, 30 mg, 60mg, and 90 mg are an AB-rated generic equivalent to the reference listed drug (RLD), ADALAT® CC of Alvogen […]
